Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (CF) (2021 - 2026)

Amylyx Pharmaceuticals' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $100000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 50.0% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $400000.0 (down 50.0% YoY), while the FY2025 annual figure was $500000.0, down 44.44% from the prior year.
• Depreciation & Amortization (CF) was $100000.0 for Q1 2026 at Amylyx Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $302000.0 in Q3 2023 to a low of $35000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $180882.4 across 5 years, with a median of $200000.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) surged 1550.0% in 2022, then sank 50.0% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $182000.0 in 2022, then surged by 65.38% to $301000.0 in 2023, then tumbled by 33.55% to $200000.0 in 2024, then tumbled by 50.0% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $100000.0 (Q1 2026), $100000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.